Jump to: Page Content, Section Navigation, Site Navigation, Site Search, Account Information, or Site Tools.
|
|
Sci. STKE, 23 March 2004 EDITORIAL GUIDESFocus Issue: Targeting Signaling Pathways for Drug DiscoveryNancy R. Gough1*, Elizabeth M. Adler2, and L. Bryan Ray3
1Managing Editor of Science's STKE, American Association for the Advancement of Science, 1200 New York Avenue, N.W., Washington, DC 20005, USA. Summary: This STKE Focus Issue on processes, targets, and opportunities in drug discovery is part of a coordinated effort to cover a broad range of topics related to drug discovery in Science's multiple online products and in a special issue of Science itself. STKE features three Perspectives and one Review that highlight drug development and signaling targets for therapeutic development. Shen describes the production of natural bioactive products by combinatorial biosynthesis in bacteria. Philips describes anticancer therapies aimed at the oncogenic guanosine triphosphatase Ras, and Kaelin discusses whether common cancers are likely to yield to single anticancer agents and echo the rousing success of the kinase inhibitor Gleevec. Charney and Manji discuss how an increased understanding of the underlying pathways could lead to novel potential therapies for treating depression. *Corresponding author. E-mail: ngough{at}aaas.org
Citation: N. R. Gough, E. M. Adler, L. B. Ray, Focus Issue: Targeting Signaling Pathways for Drug Discovery. Sci. STKE 2004, eg5 (2004). The editors suggest the following Related Resources on Science sites:In Science Signaling
In Science Magazine |
Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882